Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: A Meta-analysis.
Sign Up to like & getrecommendations! Published in 2020 at "JAMA cardiology"
DOI: 10.1001/jamacardio.2020.4511
Abstract: Importance Sodium-glucose cotransporter 2 (SGLT2) inhibitors favorably affect cardiovascular (CV) and kidney outcomes; however, the consistency of outcomes across the class remains uncertain. Objective To perform meta-analyses that assess the CV and kidney outcomes of… read more here.
Keywords: sglt2 inhibitors; death; patients type; type diabetes ... See more keywords
Indirect comparison of SGLT2 inhibitors in patients with established heart failure: evidence based on Bayesian methods
Sign Up to like & getrecommendations! Published in 2023 at "ESC Heart Failure"
DOI: 10.1002/ehf2.14297
Abstract: Head‐to‐head comparisons among SGLT2 inhibitors treatments in established heart failure remain absent. We conducted a systematic review of dedicated heart failure trials to assess indirectly the composite outcomes and individual clinical endpoints among SGLT2 inhibitor… read more here.
Keywords: heart failure; indirect comparison; established heart; heart ... See more keywords
Emerging therapies: The potential roles SGLT2 inhibitors, GLP1 agonists, and ARNI therapy for ARNI pulmonary hypertension
Sign Up to like & getrecommendations! Published in 2022 at "Pulmonary Circulation"
DOI: 10.1002/pul2.12028
Abstract: Abstract Pulmonary hypertension (PH) is a highly morbid condition. PH due to left heart disease (PH‐LHD) has no specific therapies and pulmonary arterial hypertension (PAH) has substantial residual risk despite several approved therapies. Multiple lines… read more here.
Keywords: pulmonary hypertension; inhibitors glp1; sglt2 inhibitors; glp1 agonists ... See more keywords
Ertugliflozin, renoprotection and potential confounding by muscle wasting
Sign Up to like & getrecommendations! Published in 2021 at "Diabetologia"
DOI: 10.1007/s00125-021-05614-0
Abstract: To the Editor: The eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes (VERTIS CV) trial reported that ertugliflozin reduced the risk of the composite exploratory endpoint of sustained 40% decline in baseline creatininebased eGFR (eGFRCr),… read more here.
Keywords: creatinine; muscle; sglt2 inhibitors; muscle mass ... See more keywords
Comparing the clinical outcomes across different sodium/glucose cotransporter 2 (SGLT2) inhibitors in heart failure patients: a systematic review and network meta-analysis of randomized controlled trials.
Sign Up to like & getrecommendations! Published in 2021 at "European journal of clinical pharmacology"
DOI: 10.1007/s00228-021-03147-4
Abstract: PURPOSE Empagliflozin, dapagliflozin, canagliflozin, and ertugliflozin have been shown in randomized controlled trials to improve cardiovascular, metabolic, and renal outcomes in heart failure patients. To date, there has not been any meta-analysis examining the differences… read more here.
Keywords: sglt2 inhibitors; heart; failure patients; heart failure ... See more keywords
Can SGLT2 inhibitors prevent incident gout? A systematic review and meta-analysis
Sign Up to like & getrecommendations! Published in 2022 at "Acta Diabetologica"
DOI: 10.1007/s00592-022-01866-3
Abstract: To collate the effect of SGLT2 inhibitors (SGLT2i) on adverse gout events in people with type 2 diabetes mellitus (T2DM). PubMed/MEDLINE, Embase, and Web of Science databases were systematically searched using appropriate keywords/MeSH/Emtree terms till… read more here.
Keywords: analysis; gout; sglt2 inhibitors; incident gout ... See more keywords
A case of anti-HMGCR myopathy triggered by sodium/glucose co-transporter 2 (SGLT2) inhibitors
Sign Up to like & getrecommendations! Published in 2022 at "Neurological Sciences"
DOI: 10.1007/s10072-022-06046-3
Abstract: Inflammatory myopathies, including immune-mediated necrotizing myopathy (IMNM), are a rare and heterogeneous group of autoimmune diseases which can even involve extramuscular districts and seriously impact patients’ quality of life. We report the case of a… read more here.
Keywords: sglt2; case; glucose transporter; transporter sglt2 ... See more keywords
A Bioinformatics Investigation into the Pharmacological Mechanisms of Sodium-Glucose Co-transporter 2 Inhibitors in Diabetes Mellitus and Heart Failure Based on Network Pharmacology
Sign Up to like & getrecommendations! Published in 2021 at "Cardiovascular Drugs and Therapy"
DOI: 10.1007/s10557-021-07186-y
Abstract: Diabetes mellitus (DM) is a major risk factor for the development of heart failure (HF). Sodium-glucose co-transporter 2 (SGLT2) inhibitors have demonstrated consistent benefits in the reduction of hospitalization for HF in patients with DM.… read more here.
Keywords: sglt2 inhibitors; network; sodium glucose; heart failure ... See more keywords
SGLT2 Inhibitors and Mechanisms of Hypertension
Sign Up to like & getrecommendations! Published in 2018 at "Current Cardiology Reports"
DOI: 10.1007/s11886-018-0943-5
Abstract: Purpose of ReviewWe sought to review currently available data on the safety and efficacy of sodium-glucose cotransporter 2 (SGLT2) inhibitors in type 2 diabetes mellitus patients with hypertension.Recent FindingsInhibition of SGLT2 in the renal proximal… read more here.
Keywords: sglt2 inhibitors; inhibitors mechanisms; cardiology; type diabetes ... See more keywords
Renal Protection with SGLT2 Inhibitors: Effects in Acute and Chronic Kidney Disease
Sign Up to like & getrecommendations! Published in 2022 at "Current Diabetes Reports"
DOI: 10.1007/s11892-021-01442-z
Abstract: Purpose of Review This review offers a critical narrative evaluation of emerging evidence that sodium-glucose co-transporter-2 (SGLT2) inhibitors exert nephroprotective effects in people with type 2 diabetes. Recent Findings The SGLT2 inhibitor class of glucose-lowering… read more here.
Keywords: protection sglt2; sglt2 inhibitors; sglt2; renal protection ... See more keywords
Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors: Comparing Trial and Real World Use (Study Protocol)
Sign Up to like & getrecommendations! Published in 2017 at "Diabetes Therapy"
DOI: 10.1007/s13300-017-0229-8
Abstract: BackgroundSodium-glucose co-transporter-2 (SGLT2) inhibitors (gliflozins) are the newest class of medication available to treat type 2 diabetes (T2DM). Recent findings from the first complete cardiovascular safety trial in SGLT2 inhibitors, the Empagliflozin, Cardiovascular Outcomes, and… read more here.
Keywords: sglt2 inhibitors; real world; trial; empa reg ... See more keywords